Zepbound also slows gastric emptying, which moderates the rate at which glucose enters the bloodstream after meals, and reduces appetite through central nervous system pathways that regulate satiety
The analysis found a 23% relative risk reduction and slower eGFR decline across CKD risk groups, suggesting added renal benefits with dual GIP/GLP-1 receptor agonism
Slower digestion can contribute to GLP-1 constipation , particularly if appetite changes lead to lower fluid or fiber intake
There is no severe gastroparesis, recurrent aspiration, or refractory esophagitis
Further, the percentage of participants achieving a weight reduction of 5% or more was higher in the tirzepatide groups (85%, 89%, and 91% at 5mg, 10mg, and 15mg, respectively) compared to placebo (35%) [8]
The reaction is confined to a small area (usually 1-3 inches around the injection site) and does not spread to surrounding skin or cause systemic symptoms like fever or chills